**Royal College of Pathologists Accredited Series** 

## **Current Treatment Options in Haematological Malignancy and Support Therapy**

Thursday 15<sup>th</sup> September 2011

3 Albion Place, Leeds LS1 6JL

	Chairs:	Professor Adrian Newland, Barts and The London Professor Tim Illidge, University of Manchester	
12.30	Lunch & Registration		
13.30	Acute myeloid leukaemia		<b>Professor Alan Burnett</b> The School of Medicine, Cardiff University
14.00	New sub-cutaneous options for treatment of rare haematological malignancies		<b>Dr Simon Rule</b> Derriford Hospital, Plymouth
14.20	Current NCRI trials in lymphoma		<b>Dr Andrew McMillan</b> Nottingham City Hospital
14.45	Chronic myeloid leukaemia		<b>Professor Richard Clark</b> Royal Liverpool University Hospital
15.10	Current thinking in MCL		<b>Dr Simon Rule</b> Derriford Hospital, Plymouth
15.30	Tea & Coffee		
15.50	Supportive care in haematological malignancies		<b>Dr Emma Morris</b> University College London
16.15	Myeloma update:		
	What's new in trials &	treatment	<b>Professor Graham Jackson</b> Royal Victoria Infirmary, Newcastle
	Combination therapies	– are they the future?	<b>Dr Gordon Cook</b> St James's University Hospital, Leeds
17.05	Use of immunoconjugates in lymphoma		<b>Professor Tim Illidge</b> University of Manchester
17.35	Management of MDS including supportive care		<b>Professor David Bowen</b> Leeds Teaching Hospitals
18.00	Close		

## **Registration fee of £30 to cover your catering costs**

## For online registration please visit www.hartleytaylor.co.uk

For further information or to request a registration form please contact Dominique on 01844 275650 or <u>dom@hartleytaylor.co.uk</u>

This meeting is kindly being supported by Celgene, Gilead, GlaxoSmithKline, Lipomed GmbH, MSD Oncology, Pfizer & Therakos











The sponsors have had no input into the agenda, topics or choice of speakers, however they have provided a financial contribution to the cost of running this meeting. GlaxoSmithKline has contributed towards the cost of running this meeting. GlaxoSmithKline has had no input into the content of this meeting.